TABLE 4.

Predictors of GVHD after liver transplant hospitalization

	Univariate analysis	Multivariate analysis
Age (y)	0.98 (0.97–1.00), 0.104
Female (%)	1.42 (0.76–2.67), 0.275
Elixhauser comorbidity index	0.90 (0.71–1.14), 0.383
Diabetes mellitus	1.15 (0.72–1.82), 0.567
Types of liver disease (%)
Viral hepatitis	0.78 (0.47–1.30), 0.342
Alcohol-associated liver disease	0.57 (0.35–0.93), 0.024	0.57 (0.35–0.92), 0.022
Autoimmune hepatitis	0.96 (0.41–2.28), 0.931
Acute liver failure	0.65 (0.36–1.17), 0.150
Primary sclerosing cholangitisa	0.51 (0.07–3.71), 0.509
Primary liver cancer	0.93 (0.56–1.53), 0.773
Secondary diagnosis of COVID-19 on index admission (%)	21.30 (2.80–161.91), 0.003	23.16 (3.07–177.79), 0.002

Numbers listed: HR values shown with 95% CI in parenthesis and p value after comma.

^aOnly after September of 2015, because there was no specific code for primary sclerosing cholangitis in the ICD-9 era.

Abbreviations: GVHD, graft-versus-host disease; ICD-9, International Classification of Diseases 9th Revision.